



[Skip to content](#)

Advertisement



Menu

- [Explore journals](#)
- [Get published](#)
- [About BMC](#)
- [Login My Account](#)
- 

Search all BMC articles 

[Journal of the International Society of Sports Nutrition](#)

Menu

- [Home](#)
- [About](#)
- [Articles](#)
- [Submission Guidelines](#)

Table of Contents

1. [Abstract](#)
2. [Background](#)
3. [Methods](#)
4. [Results](#)
5. [Discussion](#)
6. [Conclusion](#)
7. [Declarations](#)
8. [References](#)

- Research article
- Open Access

Comparison of new forms of creatine in raising plasma creatine levels

- Ralf Jäger¹[Email author](#),
- Roger C Harris²,
- Martin Purpura¹ and
- Marc Francaux³

Journal of the International Society of Sports Nutrition 2007 4:17

<https://doi.org/10.1186/1550-2783-4-17>

© Jäger et al; licensee BioMed Central Ltd. 2007

- **Received:** 28 September 2007
- **Accepted:** 12 November 2007
- **Published:** 12 November 2007

[Abstract](#)

Background

Previous research has shown that plasma creatine levels are influenced by extracellular concentrations of insulin and glucose as well as by the intracellular creatine concentration. However, the form of creatine administered does not appear to have any effect although specific data on this is lacking. This study examined whether the administration of three different forms of creatine had different effects on plasma creatine concentrations and pharmacokinetics.

Methods

Six healthy subjects (three female and three male subjects) participated in the study. Each subject was assigned to ingest a single dose of isomolar amounts of creatine (4.4 g) in the form of creatine monohydrate (CrM), tri-creatine citrate (CrC), or creatine pyruvate (CrPyr) using a balanced cross-over design. Plasma concentration curves, determined over eight hours after ingestion, were subject to pharmacokinetic analysis and primary derived data were analyzed by repeated measures ANOVA.

Results

Mean peak concentrations and area under the curve (AUC) were significantly higher with CrPyr (17 and 14%, respectively) in comparison to CrM and CrC. Mean peak concentration and AUC were not significantly different between CrM and CrC. Despite the higher peak concentration with CrPyr there was no difference between the estimated velocity constants of absorption (k_a) or elimination (k_{el}) between the three treatments. There was no effect of treatment with CrPyr on the plasma pyruvate concentration.

Conclusion

The findings suggest that different forms of creatine result in slightly altered kinetics of plasma creatine absorption following ingestion of isomolar (with respect to creatine) doses of CrM, CrC and CrPyr although differences in k_a could not be detected due to the small number of blood samples taken during the absorption phase. Characteristically this resulted in higher plasma concentrations of creatine with CrPyr. Differences in bioavailability are thought to be unlikely since absorption of CrM is already close to 100%. The small differences in kinetics are unlikely to have any effect on muscle creatine elevation during periods of creatine loading.

Keywords

- Pyruvate
- Creatine
- High Plasma Concentration
- Creatine Supplementation
- Familiarization Session

Background

Creatine supplementation has been reported to increase muscle creatine and phosphorylcreatine content by 5 to 30% [1]. However, significant intra-subject variability has been reported in regards to the magnitude that creatine stores and performance are affected [1, 2, 3]. Initial evidence reported by Chanutin [4] and recently confirmed by Deldicque et al. [5] indicates that intestinal absorption of creatine supplied as the monohydrate is close to 100%.

The aim of this pilot study was to compare the effects of ingesting isomolar amounts of creatine (4.4 g) in the form of the monohydrate (5 g), tri-creatine citrate (6.7 g) and creatine pyruvate (7.3 g) on creatine concentrations in plasma. The study was prompted by the fact that salts of creatine are more quickly taken up into solution than the monohydrate, and thus could offer advantages over the monohydrate. The inclusion of the small amounts of pyruvate and citrate were thought unlikely to influence creatine absorption and uptake, although initial studies with 25 g pyruvate plus 75 g dihydroxyacetone have indicated an ergogenic effect of pyruvate supplementation through a proposed stimulation of glucose uptake by muscle [6]. However, no blood samples were taken in that study to measure plasma pyruvate levels during the period of oral supplementation [6, 7]. Smaller doses of calcium pyruvate [6–10 g/d], on the other hand, showed mixed results in clinical trials [8, 9, 10]. Acute calcium pyruvate supplementation of 7 g, 15 g or 25 g did not result in any significant elevation of blood pyruvate levels [11] and consumption of 7 g/d for 7 days did not result in improved aerobic endurance in well-trained athletes [11, 12].

Methods

Subjects

Three females and three males participated in this pilot study. All subjects in this investigation participated in a familiarization session. During the familiarization session, subjects were informed as to the experimental procedures, completed a personal/medical history form, creatine supplementation history form and signed informed consent statements in adherence with the human subject's guidelines of the American College of Sports Medicine. The study was approved by the Ethical Review Committee of the University of Chichester. Subject

characteristics are presented in table 1. No subject in this trial was a vegetarian with all subjects reportedly consuming meat in their daily diet.

Table 1

Subjects characteristics

No.	Sex	Age (years)	Weight (kg)	Height (m)
1	M	21	84	1.82
2	M	29	87	1.82
3	M	22	78	1.86
4	F	55	70	1.58
5	F	51	65	1.62
6	F	35	68	1.65

Supplementation Protocol

The study used a cross-over design. Each subject received the three treatments using a latin-square design on three different days, with 7 days allowed between each treatment. Treatments comprised:

A: 5 g Creatine monohydrate (CrM) dissolved in 450 ml of water (control)

B: 6.7 g Tri-creatine citrate (CrC) dissolved in 450 ml of water (isomolar with respect to creatine to A and C)

C: 7.3 g Creatine pyruvate (CrPyr) dissolved in 450 ml of water (isomolar with respect to creatine to A and B).

The creatine monohydrate (Creapure™) contains 88% w/w creatine, creatine pyruvate (Creapure™Pyruvate) contains 60% w/w creatine and 40% w/w pyruvate, and, tri-creatine citrate (Creapure™Citrate) contains 65% w/w creatine. All three were obtained from Degussa AG (Trostberg, Germany) and contained <100 ppm creatinine, whilst dicyandiamide and dihydrotriazine levels and polymeric pyruvates in CrPyr were not detectable by HPLC.

Procedures

Two ml blood samples were collected into tubes containing lithium heparin through an antecubital vein, centrifuged and plasma was harvested and stored frozen until analysed.

Plasma (500 µl) was extracted with 15 µl of 70% w/w PCA and supernatants after centrifugation were neutralised with a minimum volume of 2N KHCO₃ at 4°C. One hundred and sixty one blood samples, from an intended 162, were collected. Data for from the missing sample (subject 1, treatment C, 2 hours) were estimated from the two adjacent points assuming an exponential decrease between 1.5 to 3 hours. Creatine in plasma extracts was analysed photometrically by following the oxidation of NADH at 340 nm in the presence of creatine kinase, pyruvate kinase and lactate dehydrogenase [13]. Pyruvate was analysed using a similar assay but with the addition of lactate dehydrogenase only.

Pharmacokinetics

Using a Marquardt algorithm, all kinetics were fitted with the following equation:

$$C = (FD/V * (ka / (ka - kel)) * (exp(-kel*t) - exp(-ka*t)))$$

Where:

C is the plasma creatine concentration minus the basal concentration (µM)

if $C \leq 0$, then data were removed

F is the bioavailability

D is the dose (5 g or 38.17 mmol)

V is the volume of distribution

ka is the velocity constant of absorption (first order, h⁻¹)

kel is the velocity constant of elimination (first order, h⁻¹)

t is the time (h)

No weight was applied to data (weight = 1) and the initial parameters values were estimated using a Simplex algorithm. This equation corresponds to a one-open compartmental model. The area under the curve (AUC) from zero to infinity was estimated by non compartmental model

Statistical Analysis

Results are shown as means together with standard deviation. Primary and derived variables were analysed by repeated measures ANOVA. Where a significant effect of treatment was indicated, data were further compared using a Bonferroni post-hoc test. The threshold for significance was set at $p < 0.05$.

Results

Mean (SD) plasma concentrations following the three treatments are shown in table 2 and the mean curves are depicted in figure 1. One hour after the ingestion, the plasma creatine concentration was higher with CrPyr than with CrC ($p = 0.024$, table 2). The difference between means was larger when CrPyr and CrM were compared, but in this last case the signification threshold was not reached ($p = 0.089$).

Table 2

Mean (SD) plasma creatine concentration over 8 hours following ingestion of isomolar amounts of creatine (4.4 g) in the form of creatine monohydrate (CrM), tri-creatine citrate (CrC), or creatine pyruvate (CrPyr). Means within each time-row differing significantly are denoted by the letters a to c.

Time (h)	CrM (a)		CrC (b)		CrPyr (c)		ANOVA P value
	Mean	SD	Mean	SD	Mean	SD	
0	40.5	25.5	56.5	36.7	44	28	NS
0.5	488.6	185.7	551.1	191.3	637	207.2	NS
1	761.9	107.7	855.3 c	165.1	972.2 a	184.1	0.015
1.5	660.8	159.2	771.8	289.3	875.7	310.9	0.012
2	557	162.1	624.2	263.1	681.7	299.4	NS
3	362.5	174.4	400.1	235.7	431.5	228.5	NS
4	247.8	134.8	276	169.3	298	176.3	NS
6	142.7	87.3	189.1	120.2	178.5	110.3	NS
8	103.4	64.5	123.1	83.6	122.9	83.7	NS

Figure 1

Mean plasma creatine concentration over 8 hours following ingestion of 4.4 g of Creatine in the form of creatine monohydrate (CrM), tri-creatine citrate (CrC), or creatine pyruvate (CrPyr). Dispersions and statistical significances are given in table 2.

Peak concentrations were always the highest after ingestion of CrPyr. Mean peak concentrations were 1.17 fold higher with CrPyr compared to CrC ($p = 0.010$) and 1.29 fold higher than with CrM, but again missing the threshold of significance ($p = 0.075$, table 3). The time at which the peak concentrations were reached (T_{max}) was unaffected by the form of creatine ingested as well as the velocity constants of absorption (k_a) and elimination (k_e) (table

3). The mean half-life of elimination was 30 ± 11.6 min. AUC values with CrPyr were also the highest in all subjects. Mean AUC with CrPyr was 1.14 fold higher compared to CrC although the difference did not reach the threshold of significance ($P = 0.069$).

Table 3

Mean (SD) peak plasma concentration (Cr_{max} , mM), time to peak concentration (T_{max} , h), area under the plasma concentration curve (AUC, mM.h), velocity constant of absorption (k_a , h^{-1}) and velocity constant of elimination (k_e , h^{-1}) following ingestion of isomolar amounts of creatine (4.4 g) in the form of creatine monohydrate (CrM), tri-creatine citrate (CrC), or creatine pyruvate (CrPyr). Means differing significantly are denoted by the letters a to c.

	CrM (a)		CrC (b)		CrPyr (c)		ANOVA P value
	Mean	SD	Mean	SD	Mean	SD	
Cr_{max}	751	32.9	837 c	71.5	968 a	82.3	0.008
T_{max}	1.5 c	0.13	1.2	0.1	1.1 a	0.08	0.002
AUC	2384	376.5	2627	506.8	2985	540.6	0.023
ka	1.26	0.214	1.39	0.551	1.31	0.324	NS
kel	0.73	0.344	0.66	0.279	0.72	0.279	NS

There was no effect of treatments on the plasma pyruvate concentrations (figure 2).

Figure 2

Mean plasma pyruvate concentrations during 8 hours following ingestion of creatine pyruvate (CrPyr, 7.3 g), creatine monohydrate (CrM, 5 g) or tri-creatine citrate (CrC, 6.7 g).

Discussion

Although creatine is widely used as a dietary supplement, only a few studies describe data relevant to its pharmacokinetics [1, 5, 14, 15, 16, 17, 18, 19]. After ingestion of a single low dose, the time-course of the changes in plasma concentration is generally accepted to follow a one-open compartment model with first-order absorption and elimination constants [20]. The present results support this model.

All treatments at all doses resulted in substantial increases in plasma creatine which if repeated could be expected to lead to enhancement of the creatine content in muscle [1, 2]. However, some differences were apparent in the dynamics of plasma creatine following ingestion of isomolar (with respect to creatine) doses of CrM, CrC and CrPyr. Characteristically this resulted in higher plasma concentrations of creatine with CrPyr. This may suggest that faster absorption or slower elimination of creatine when supplied as CrPyr although this was not evident from the estimates of k_a and k_{el} . Faster absorption of creatine could, for instance occur, as a result of an increase in metabolisable substrate (i.e. pyruvate or citrate) for use by enterocytes. It is likely that the small change in k_a was missing due to the small number of blood samples taken during the absorption phase, namely 3–4 samples. Higher plasma concentrations could also indicate suppression of uptake by muscle, possibly through the lowering of insulin in the circulation or due to changes in plasma pH as a result of the metabolism of pyruvate and citrate supplied, but this is not supported by the k_{el} values which were calculated over a larger number of data points. The higher plasma concentration with CrPyr is unlikely to have been due to greater bioavailability, since the bioavailability of CrM is known to be close to 100% [4, 5]. Differences in muscular creatine levels during and after supplementation would be needed to allow a difference in muscular performance. It is questionable if the small differences observed in the plasma concentrations with the three treatments would have any effect on the increase in creatine in muscle. However, this would need to be confirmed by direct measurement.

The inability to detect any change in the plasma pyruvate concentration is attributed to the rapid clearance and metabolism of this by the liver; although decarboxylation in the stomach and intestine and/or elimination through the urine or faeces [10] are also possibilities.

Conclusion

The findings suggest that different forms of creatine result in slightly altered kinetics of plasma creatine absorption following ingestion of isomolar (with respect to creatine) doses of CrM, CrC and CrPyr although differences in k_a could not be detected due to the small number of blood samples taken during the absorption phase. Characteristically this resulted in higher plasma concentrations of creatine with CrPyr. Differences in bioavailability are thought to be unlikely since absorption of CrM is already close to 100%.

Declarations

Acknowledgements

The authors would like to thank Degussa BioActives GmbH (Freising, Germany) for funding this research.

Authors' original submitted files for images

Below are the links to the authors' original submitted files for images.

[12970_2007_52_MOESM1_ESM.pdf](#) Authors' original file for figure 1

[12970_2007_52_MOESM2_ESM.pdf](#) Authors' original file for figure 2

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

RH, RJ and MP participated in the design of the study. RH organized the blood collection and assayed the samples, and, together with MF analyzed the results statistically. MF performed the pharmacokinetic analysis of the data, and, RJ, RH and MF drafted the manuscript. All authors have read and approved the final manuscript.

Authors' Affiliations

(1)

Increnovo LLC, 2138 E Lafayette Pl, Milwaukee, WI 53202, USA

(2)

School of Sport, Exercise and Health Sciences, University College Chichester, College Lane, Chichester, West Sussex, PO19 4PE, UK

(3)

Institut d'Education physique et de Readaptation, Universite catholique de Louvain, Louvain-la-Neuve, Belgium

References

1. Harris RC, Söderlund K, Hultman E: Evaluation of Creatine in resting and exercised muscle of normal subjects by Creatine supplementation. *Clin Sci (Lond)*. 1992, 83 (3): 367-374.[View ArticleGoogle Scholar](#)
2. Terjung RL, Clarkson P, Eichner ER, Greenhaff PL, Hespel PJ, Israel RG, Kraemer WJ, Meyer RA, Spriet LL, Tarnopolsky MA, Wagenmakers AJM, Williams MH: The American College of Sports Medicine Roundtable on the physiological and health effects of oral creatine supplementation. *Med Sci Sports Exerc*. 2000, 32 (3): 706-717. 10.1097/00005768-200003000-00024.[View ArticlePubMedGoogle Scholar](#)
3. Williams MH, Kreider RB, Branch JD: Creatine: the power supplement. 1999, Champaign: Human Kinetics[Google Scholar](#)
4. Chanutin A: The fate of creatine when administered to man. *J Biol Chem*. 1926, 67 (1): 29-41.[Google Scholar](#)
5. Deldicque L, Décombaz J, Zbinden Foncea H, Vuichoud J, Poortmans JR, Francaux M: Kinetics of creatine ingested as a food ingredient. *Eur J Appl Physiol*. 2008, 102 (2): 133-143. 10.1007/s00421-007-0558-9.[View ArticlePubMedGoogle Scholar](#)
6. Stanko RT, Robertson RJ, Galbreath RW, Reilly JJ, Greenawalt KD, Goss FL: Enhanced leg exercise endurance with a high-carbohydrate diet and dihydroxyacetone and pyruvate. *J Appl Physiol*. 1990, 69 (5): 1651-1656.[PubMedGoogle Scholar](#)
7. Stanko RT, Robertson RJ, Spina RJ, Reilly JJ, Greenawalt KD, Goss FL: Enhancement of arm exercise endurance capacity with dihydroxyacetone and pyruvate. *J Appl Physiol*. 1990, 68 (1): 119-124.[PubMedGoogle Scholar](#)
8. Kalman D, Colker CM, Wilers I, Routs JB, Antonio J: The effects of pyruvate supplementation on body composition in overweight individuals. *Nutrition*. 1999, 15 (5): 337-340. 10.1016/S0899-9007(99)00034-9.[View ArticlePubMedGoogle Scholar](#)
9. Stone MH, Sanborn K, Smith LL, O'Bryant HS, Hoke T, Utter AC, Johnson RL, Boros R, Hruby J, Pierce KC, Stone ME, Garner B: Effects of in-season (5 weeks) creatine and

- pyruvate supplementation on aerobic performance and body composition in American football players. *Int J Sport Nutr.* 1999, 9 (2): 146-165.[PubMedGoogle Scholar](#)
10. Koh-Banerjee PK, Ferrerira MP, Greenwood M, Bowden RG, Cowen PN, Almada AL, Kreider RB: Effects of Calcium Pyruvate supplementation during training on body composition, exercise capacity, and metabolic responses to exercise. *Nutrition.* 2005, 21 (3): 312-319. 10.1016/j.nut.2004.06.026.[View ArticlePubMedGoogle Scholar](#)
 11. Morrison MA, Spriet LL, Dyck DJ: Pyruvate ingestion for 7-days does not improve aerobic performance in well-trained individuals. *J Appl Physiol.* 2000, 89: 549-556.[PubMedGoogle Scholar](#)
 12. Van Schuylenbergh R, Van Leemputte M, Hespel P: Effects of oral creatine-pyruvate supplementation in cycling performance. *Int J Sports Med.* 2003, 24 (2): 144-150. 10.1055/s-2003-38400.[View ArticlePubMedGoogle Scholar](#)
 13. Harris RC, Hultman E, Nordesjö LO: Glycogen, glycolytic intermediates and high energy phosphates in biopsy samples of musculus quadriceps femoris of man at rest. Methods and variance of values. *Scand J Clin Lab Invest.* 1974, 33 (2): 109-120. 10.3109/00365517409082477.[View ArticlePubMedGoogle Scholar](#)
 14. Fitch CD, Sinton DW: A Study of Creatine Metabolism in Diseases Causing Muscle Wasting. *J Clin Invest.* 1964, 43: 444-452.[PubMed CentralView ArticlePubMedGoogle Scholar](#)
 15. Green AL, Hultman E, Macdonald IA, Sewell DA, Greenhaff PL: Carbohydrate ingestion augments skeletal muscle creatine accumulation during creatine supplementation in humans. *Am J Physiol.* 1996, 271: E821-826.[PubMedGoogle Scholar](#)
 16. Schedel JM, Tanaka H, Kiyonaga A, Shindo M, Schutz Y: Acute creatine ingestion in human: consequences on serum creatine and creatinine concentrations. *Life Sci.* 1999, 65 (23): 2463-2470. 10.1016/S0024-3205(99)00512-3.[View ArticlePubMedGoogle Scholar](#)
 17. Vanakoski J, Kosunen V, Meririnne E, Seppala T: Creatine and caffeine in anaerobic and aerobic exercise: effects on physical performance and pharmacokinetic considerations. *Int J Clin Pharmacol Ther.* 1998, 36 (5): 258-262.[PubMedGoogle Scholar](#)
 18. Persky AM, Müller M, Derendorf H, Grant M, Brazeau GA, Hochhaus G: Single- and multiple-dose pharmacokinetics of oral creatine. *J Clin Pharmacol.* 2003, 43 (1): 29-37. 10.1177/0091270002239703.[View ArticlePubMedGoogle Scholar](#)
 19. Rawson ES, Clarkson PM, Price TB, Miles MP: Differential response of muscle phosphocreatine to creatine supplementation in young and old subjects. *Acta Phys Scand.* 2002, 174 (1): 57-65. 10.1046/j.1365-201x.2002.00924.x.[View ArticleGoogle Scholar](#)
 20. Persky AM, Brazeau GA, Hochhaus G: Pharmacokinetics of the dietary supplement creatine. *Clin Pharmacokinet.* 2003, 42 (6): 557-574. 10.2165/00003088-200342060-00005.[View ArticlePubMedGoogle Scholar](#)

Copyright

© Jäger et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

[Download PDF](#)

[Download ePub](#)

Export citations

Papers, Zotero, Reference Manager, RefWorks (.RIS)

- [↓ Download Citations](#)
- [↓ Download References](#)
- [↓ Download Both](#)

EndNote (.ENW)

- [↓ Download Citations](#)
- [↓ Download References](#)
- [↓ Download Both](#)

Mendeley, JabRef (.BIB)

- [↓ Download Citations](#)
- [↓ Download References](#)
- [↓ Download Both](#)

Metrics

- Article accesses: 18611
- Citations: 15 [more information](#)
- Altmetric Attention Score: 33



Share this article

- Share on Twitter 
- Share on Facebook 
- Share on LinkedIn 
- Share on Weibo 
- Share on Google Plus 
- Share on Reddit 

Other Actions

- [Order reprint](#)

Advertisement

Journal of the International Society of Sports Nutrition

ISSN: 1550-2783

Contact us

- Submission enquiries: [Access here and click Contact Us](#)
- General enquiries: info@biomedcentral.com

■ BMC


- [Explore journals](#)
- [Get published](#)
- [About BMC](#)

- [Read more on our blogs](#)
- [Receive BMC newsletters](#)
- [Manage article alerts](#)
- [Language editing for authors](#)
- [Scientific editing for authors](#)

- [Policies](#)
- [Accessibility](#)
- [Press center](#)

- [Contact us](#)
- [Leave feedback](#)
- [Careers](#)

Follow BMC

- [BMC Twitter page](#) 
- [BMC Facebook page](#) 
- [BMC Google Plus page](#) 
- [BMC Weibo page](#) 

By using this website, you agree to our [Terms and Conditions](#), [Privacy statement](#) and [Cookies](#) policy. [Manage the cookies](#) we use in the preference centre.

SPRINGER NATURE

© 2018 BioMed Central Ltd unless otherwise stated. Part of [Springer Nature](#).